Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Andrew Ahmann(Oregon Health & Science University), Vanita R. Aroda(Brigham and Women's Hospital), G. Charpentier(Centre Hospitalier Sud Francilien), Ildiko Lingvay(Southwestern Medical Center), Elena Henkel(GWT-TUD (Germany)), Francesco Dotta(University of Chieti-Pescara), Matthew Capehorn(Rotherham General Hospital), Miriam Annett(Novo Nordisk (United States)), Anders G. Holst(Novo Nordisk (Denmark))
Cited by 574
Related Papers
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|2.4k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetologia|2022|986
9. Pharmacologic Approaches to Glycemic Treatment: <i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|850